The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1156
May 12, 2003
View Complete Issue         Table of Contents 2019 
Oxybutynin Transdermal (Oxytrol) for Overactive Bladder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oxybutynin Transdermal (Oxytrol) for Overactive Bladder
May 12, 2003 (Issue: 1156)
A patch formulation of oxybutynin (Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry mouth.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Oxybutynin Transdermal (Oxytrol) for Overactive Bladder
Article code: 1156b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.